PMID- 21255135
OWN - NLM
STAT- MEDLINE
DCOM- 20120629
LR  - 20110414
IS  - 1365-2222 (Electronic)
IS  - 0954-7894 (Linking)
VI  - 41
IP  - 5
DP  - 2011 May
TI  - Intravenous immunoglobulin attenuates airway hyperresponsiveness in a murine 
      model of allergic asthma.
PG  - 718-28
LID - 10.1111/j.1365-2222.2010.03663.x [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) has potent anti-inflammatory and 
      immune-modulating properties. IVIG has been utilized as a steroid-sparing agent 
      in severe asthma, but the results of clinical trials have been conflicting. 
      OBJECTIVE: To determine whether IVIG is able to attenuate bronchial reactivity, 
      pulmonary inflammation and T cell function using a murine model of allergic 
      airways disease. METHODS: BALB/c or C57BL/6 mice were sensitized to ovalbumin 
      (OVA) or a phosphate-buffered saline control using local nasal sensitization, and 
      then received five intranasal challenges on days 28-32 before sacrifice. Mice 
      were treated intraperitoneally with either IVIG (1-2 g/kg) or equivalent human 
      serum albumin 24 h before the first OVA challenge. Bronchial reactivity to 
      methacholine was examined using the FlexiVent small animal ventilator. We 
      evaluated pulmonary histology, mRNA from lung digests for T-helper type 2 
      (Th2)-related genes and bronchoalveolar lavage for cell counts and cytokines. 
      Splenocytes were utilized to study OVA-induced cell proliferation, cytokine 
      production and dendritic cell maturation. RESULTS: IVIG markedly attenuated the 
      perivascular and peribronchial pulmonary inflammation, and decreased bronchial 
      hyperresponsiveness to methacholine. IVIG treatment of splenocytes from 
      sensitized animals diminished cellular proliferation to OVA, whereas IVIG 
      treatment in vivo markedly attenuated OVA-driven splenocyte proliferation. This 
      is accompanied by diminished IL-13 and TNF-alpha levels in splenocyte culture, 
      decreased expression of Jagged-1, increased Delta-4 and decreased GATA-3 mRNA 
      levels, signs that IVIG has suppressed the expected Th2 response that accompanies 
      repeated allergen exposure. Increased regulatory T cells were found in draining 
      pulmonary lymph nodes in IVIG-treated mice but not in controls. CONCLUSIONS AND 
      CLINICAL RELEVANCE: IVIG was effective in ameliorating allergic airway disease in 
      our model. IVIG may be a promising adjunct therapy requiring further study for 
      patients with severe asthma.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Kaufman, G N
AU  - Kaufman GN
AD  - Meakins Christie Laboratories, Montreal, QC, Canada.
FAU - Massoud, A H
AU  - Massoud AH
FAU - Audusseau, S
AU  - Audusseau S
FAU - Banville-Langelier, A-A
AU  - Banville-Langelier AA
FAU - Wang, Y
AU  - Wang Y
FAU - Guay, J
AU  - Guay J
FAU - Garellek, J A
AU  - Garellek JA
FAU - Mourad, W
AU  - Mourad W
FAU - Piccirillo, C A
AU  - Piccirillo CA
FAU - McCusker, C
AU  - McCusker C
FAU - Mazer, B D
AU  - Mazer BD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110124
PL  - England
TA  - Clin Exp Allergy
JT  - Clinical and experimental allergy : journal of the British Society for Allergy 
      and Clinical Immunology
JID - 8906443
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Serum Albumin)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Asthma/chemically induced/*immunology
MH  - Bronchial Hyperreactivity/immunology/*therapy
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunoglobulins, Intravenous/immunology/*therapeutic use
MH  - Injections, Intraperitoneal
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - *Models, Immunological
MH  - Ovalbumin
MH  - Serum Albumin/administration & dosage/immunology
MH  - T-Lymphocytes, Regulatory/immunology
EDAT- 2011/01/25 06:00
MHDA- 2012/06/30 06:00
CRDT- 2011/01/25 06:00
PHST- 2011/01/25 06:00 [entrez]
PHST- 2011/01/25 06:00 [pubmed]
PHST- 2012/06/30 06:00 [medline]
AID - 10.1111/j.1365-2222.2010.03663.x [doi]
PST - ppublish
SO  - Clin Exp Allergy. 2011 May;41(5):718-28. doi: 10.1111/j.1365-2222.2010.03663.x. 
      Epub 2011 Jan 24.